Post-thrombolysis intracerebral hemorrhage: Data from the Spanish Register ARIAM*

Ruiz-Bailén, Manuel; Brea-Salvago, J.F.; Hoyos, Eduardo Aguayo de; Rucabado-Aguilar, Luis; Martínez-Escobar, Sergio; Rossel-Ortiz, Fernando; Mellado-Vergel, José Francisco; Ruiz-Ferrón, Francisco; Morante-Valle, Antonia; Gómez-Jiménez, Francisco Javier; Colmenero, Manuel

doi:10.1097/01.ccm.0000171538.61759.09

Cited by 15 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, if anything, our analysis underestimates the incidence as compared with clinical studies and registries,17 which have used different definitions of major bleeding, including various levels of drop in haemoglobin or haematocrit 18. Intracranial bleeding complications of 0.8% in this study seem to be in line with previously published data from both clinical trials1 13 14 and registers 6–8 19…”

Section: Discussionsupporting

confidence: 85%

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Oldgren

Wernroth

Stenestrand

2010

Heart

View full text Add to dashboard Cite

During 2001 to 2006 the use of fibrinolytic treatment markedly decreased while the incidence of major bleeding complications more than doubled. The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolytic agents. Future close monitoring of bleeding complications is warranted, especially when considering the increased use of various combinations of antithrombotic drugs in conjunction with fibrinolysis and the great impact of bleeding on long-term mortality.

show abstract

Section: Discussionsupporting

confidence: 85%

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Oldgren

Wernroth

Stenestrand

2010

Heart

View full text Add to dashboard Cite

show abstract

“…According to several previous studies, the major drawback of CDT therapy is hemorrhagic complications, which have been related to prolonged treatment duration. 13,25 In our study, we did not observe any major bleeding complications, probably due to the small sample size, a shorter thrombolysis time compared with previous studies, and the daily measurement of the fibrinogen level. In addition, Yang et al 16 reported that patients with acute iliofemoral deep venous thrombosis who underwent PMT using AngioJet had an increased risk of postoperative acute kidney injury (AKI) compared with those who underwent CDT.…”

Section: Discussioncontrasting

confidence: 57%

Comparison of catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy for subacute iliofemoral deep vein thrombosis

Zhong

Yang

et al. 2020

Phlebology

View full text Add to dashboard Cite

Objective To evaluate and compare the treatment efficacy and safety between catheter-directed thrombolysis monotherapy and catheter-directed thrombolysis combined with percutaneous mechanical thrombectomy for patients with subacute iliofemoral deep vein thrombosis. Methods We conducted a retrospective analysis of a total of 74 subacute iliofemoral deep vein thrombosis patients who underwent catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy. Patients treated with catheter-directed thrombolysis combined with percutaneous mechanical thrombectomy (percutaneous mechanical thrombectomy group, n = 30) or catheter-directed thrombolysis monotherapy (catheter-directed thrombolysis group, n = 44) were included. The primary endpoints were the clinical efficacy rate of thrombolysis, primary patency, and the incidence of post-thrombotic syndrome (at 12 months diagnosed according to the original Villalta score criteria. Secondary endpoints were the total urokinase dose, the thrombolysis time, the detumescence rate and complications. Results The percentage of successful thrombolysis for percutaneous mechanical thrombectomy group was higher than that for catheter-directed thrombolysis group ( P = 0.045). At the 12-month follow-up, there was no difference in the primary patency ( P > 0.05) or the incidence of post-thrombotic syndrome ( P = 0.36). Percutaneous mechanical thrombectomy group had significant advantages in reducing urokinase doses and thrombolysis times compared with catheter-directed thrombolysis group for patients with thrombus clearance levels II and III ( P < 0.05). Conclusion Catheter-directed thrombolysis combined with percutaneous mechanical thrombectomy performs better in removing vein thrombi, reducing urokinase doses, and shortening thrombolysis times.

show abstract

“…In many studies, the major drawback of CDT therapy has been hemorrhagic complications, which have been related to prolonged treatment duration (17)(18)(19)(20)(21)(22)(23). Our CDT patients received a median of 21 hours' infusion of the thrombolytic agent, as opposed to 20 minutes in PMT patients.…”

Section: Kim Et Al Compared Cdt and Pmt In The Treatment Of 23 Uedvtmentioning

confidence: 99%

Catheter-Directed Thrombolysis Versus Pharmacomechanical Thrombectomy for Upper Extremity Deep Venous Thrombosis: A Cost-Effectiveness Analysis

Mahmoud

Vikatmaa

Räsänen

et al. 2018

Annals of Vascular Surgery

View full text Add to dashboard Cite

show abstract

Post-thrombolysis intracerebral hemorrhage: Data from the Spanish Register ARIAM*

Cited by 15 publications

References 39 publications

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Comparison of catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy for subacute iliofemoral deep vein thrombosis

Catheter-Directed Thrombolysis Versus Pharmacomechanical Thrombectomy for Upper Extremity Deep Venous Thrombosis: A Cost-Effectiveness Analysis

Contact Info

Product

Resources

About